DERMAWAVE 5000 COMBI MAX SYSTEM

K040121 · Dermawave, LLC · IMG · Mar 17, 2004 · Physical Medicine

Device Facts

Record IDK040121
Device NameDERMAWAVE 5000 COMBI MAX SYSTEM
ApplicantDermawave, LLC
Product CodeIMG · Physical Medicine
Decision DateMar 17, 2004
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 890.5860
Device ClassClass 2
AttributesTherapeutic, 3rd-Party Reviewed

Intended Use

Stimulation, relaxing, and/or repeatedly contracting muscles by passing electrical currents through electrodes contacting the affected body area in the medical specialties of physical medicine, general and plastic surgery and neurology and/or for use in applying therapeutic deep heat for selected medical conditions such as relief of pain, muscle spasms and joint contractures in the medical specialty of physical medicine. The indications of the DermaWave 5000 Combi Max System also include the treatment and relaxation of muscle spasms, prevention or retardation of disuse atrophy, increasing local blood circulation, muscle re-education, maintaining or increasing range of motion, immediate postsurgical stimulation of calf muscles to prevent venous thrombosis, symptomatic relief of chronic intractable pain, management of pain associated with post-traumatic or post-operative conditions using electrical stimulation and are indicated for the application of therapeutic deep heat for the treatment of selected medical conditions such as relief of pain, muscle spasms and joint contractures, relief of pain muscle spasms and joint contractures that may be associated with adhesive capsulitis, bursitis with slight calcification, myositis, soft tissue injuries, shortened tendons due to past injuries and scar tissues, relief of chronic and sub-chronic pain and joint contractures resulting from capsular tightness and capsular scarring using ultrasound. The DermaWave 5000 Combi Max System is also indicated for use in providing topical heating for temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, minor pain and stiffness associated with arthritis.

Device Story

System console with software/electronics; control/display panel; delivery accessories (electrodes, ultrasound soundheads, infrared heating accessories). Device delivers electrical stimulation, therapeutic deep heat (ultrasound), and topical heat. Used in physical medicine, surgery, and neurology clinics by healthcare providers. Console manages treatment parameters and timing. Output affects muscle activity, blood circulation, and pain perception. Benefits include pain relief, muscle rehabilitation, and prevention of atrophy/thrombosis. Sophisticated internal controls enhance safety compared to predicate consoles.

Clinical Evidence

Bench testing only. Comparative temperature charts provided to demonstrate infrared heating performance against established clinical guidelines for tissue temperature elevation.

Technological Characteristics

System console with integrated software/control electronics; ultrasound soundheads; infrared heating accessories; cutaneous electrodes. Infrared heating designed to maintain tissue temperature between 40C and 45C. System includes sophisticated control architecture for safety management.

Indications for Use

Indicated for patients requiring muscle stimulation, relaxation, or contraction; treatment of muscle spasms; prevention of disuse atrophy; muscle re-education; range of motion maintenance; venous thrombosis prevention; and pain management (chronic, intractable, post-traumatic, post-operative). Also indicated for therapeutic deep heat and topical heating for conditions including adhesive capsulitis, bursitis, myositis, soft tissue injuries, scar tissue, and arthritis-related stiffness.

Regulatory Classification

Identification

An ultrasound and muscle stimulator for use in applying therapeutic deep heat for selected medical conditions is a device that applies to specific areas of the body ultrasonic energy at a frequency beyond 20 kilohertz and that is intended to generate deep heat within body tissues for the treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies. The device also passes electrical currents through the body area to stimulate or relax muscles.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ ### Attachment 14 K040121 1 OF 3 ## 510(k) Summary Statement for the DermaWave 5000 Combi Max System #### 1. General Information | Submitter: | DermaWave LLC<br>15693 83rd Lane North<br>Loxahatchee, FL 33470 | |------------|-----------------------------------------------------------------| |------------|-----------------------------------------------------------------| Contact Person: Alan Bunting 15693 83td Lane North Loxahatchee, FL 33470 Summary Preparation Date: December 4, 2003 #### 2. Names Device Names: DermaWave 5000 Combi Max System (K040121) Primary Classification Names: 21 CFR 890.5860, IMG Class 2 Stimulator, Ultrasound - 21 CFR 882.5300, IMI Class 2 Diathermy, Ultrasonic 21 CFR 882.5890 84GZJ Class 2 Transcutaneous Electrical Nerve Stimulator (TENS) 21 CFR 882.1320 GXY Class 2 Electrode, Cutaneous 21CFR 882. 5890 LIH Interferential Current Therapy 21 CFR 890.5500 ILY Class 2 Infrared Lamp ## 3. Predicate Devices - Chatanooga Group Inc., Vectra 2C & Vectra 4C (K982317) . - Chaatanooga Group Inc. Vectra Pro 2 & Vectra Pro 4 (K982324) . - Dynatronics Corporation, Dynatron 150 Plus Ultrasound (K935728) . - Excel Tech, XL Tek Ultra VM Ultrasound (K001166) . - MedX 1000 Console (K020017) . - MedX LCT 100 Laser Accessory (K032231) . - MedX/Duolight 500 (K032231) . - MedX 600 LED Accessory (K020017) . {1}------------------------------------------------ K040121 20F3 ## 4. Product Description The DermaWave 5000 Combi Max System is comprised of the following main components: - A system console including software and control electronics. . - A control and display panel. . - · Delivery device accessories including patient cables and electrodes, ultrasound cables, soundheads, and infrared heating accessories. #### 5. Indications for Use The DermaWave 5000 Combi Max System and the delivery accessories that are used with them are indicated for use in the following: Stimulation, relaxing, and/or repeatedly contracting muscles by passing electrical currents through electrodes contacting the affected body area in the medical specialties of physical medicine, general and plastic surgery and neurology and/or for use in applying therapeutic deep heat for selected medical conditions such as relief of pain, muscle spasms and joint contractures in the medical specialty of physical medicine. The indications of the DermaWave 5000 Combi Max System also includes the treatment and relaxation of muscle spasms, prevention or retardation of disuse atrophy, increasing local blood circulation, muscle re-education, maintaining or increasing range of motion, immediate post-surgical stimulation of calf muscles to prevent venous thrombosis, symptomatic relief of chronic intractable pain, management of pain associated with posttraumatic or post-operative conditions using electrical stimulation and are indicated for the application of therapeutic deep heat for the treatment of selected medical conditions such as relief of pain, muscle spasms and joint contractures, relief of pain muscle spasms and joint contractures that may be associated with adhesive capsulitis, bursitis with slight calcification, myositis, soft tissue injuries, shortened tendons due to past injuries and scar tissues, relief of chronic and sub-chronic pain and joint contractures resulting from capsular tightness and capsular scarring using ultrasound. The DermaWave 5000 Combi Max System is also indicated for use in providing topical heating for temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, minor pain and stiffness associated with arthritis. #### 6. Rationale for Substantial Equivalence The DermaWave 5000 Combi Max System shares the same general indications for use in physical medicine, general and plastic surgery and neurology applications and share the same or similar basic characteristics and features and, therefore, are substantially equivalent to the: {2}------------------------------------------------ Image /page/2/Picture/0 description: The image shows handwritten text that appears to be a combination of alphanumeric characters. The text includes 'K040121' and '30F3', with the latter positioned below and slightly to the right of the former. The handwriting is somewhat stylized, and the text is oriented diagonally in the frame. - Chatanooga Group Inc., Vectra 2C & Vectra 4C (K982317) ♥ - Chaatanooga Group Inc. Vectra Pro 2 & Vectra Pro 4 (K982324) . - Dynatronics Corporation, Dynatron 150 Plus Ultrasound (K935728) . - Excel Tech, XL Tek Ultra VM Ultrasound (K001166) . The DermaWave 5000 Combi Max System utilizes identical accessories as those produced by MedX Health and share identical indications for use in physical medicine. Further, the MedX accessories comprising the MedX LCT 100 (K032231), MedX Duolight 500 (K032231) and the MedX 600 (K020017) are already cleared. The DermaWave 100 Accessory has almost identical heating characteristics as the MedX line of infrared lamp accessories and falls within the recommended guidelines for such devices in raising the temperature of tissue to no more then 45C in continuous operation over a set time period. The parameters used to achieve the comparative data are based on widely accepted clinical data that require heat lamp devices to elevate the temperature to above 40C and below 45C for a minimum 10 minute period. Comparative temperature charts are included in Section 10 of this submission. The MedX and Duolight cleared accessories are connected to a control console that provides treatment time information to the user. The control console supplied by MedX and named the MedX 1000/1100 Console, is limited in its control features. The DermaWave 5000 Combi Max System employs sophisticated controls and control systems within system architecture to enhance the safety of the device in applications for which it is used. ## 7. Safety and Effectiveness Information Validation documentation and a comparison of the technical characteristics and features were provided to demonstrate that the DermaWave 5000 Combi Max System is safe and effective, when indicated in specific applications in the medical specialties of physical medicine, general and plastic surgery and neurology. ## 8. Conclusion The DermaWave 5000 Combi Max System was found to be substantially equivalent to the predicate devices and share similar indications for use and characteristics and functional features and are substantially equivalent to the currently marketed predicate devices. {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it, often associated with medicine and healthcare. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the caduceus. The logo is black and white. MAR 1 7 2004 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Dermawave, LLC C/o Mr. Derwyn Reuber Intertek Testing Services NA, Inc. 70 Codman Hill Road Boxborough, Massachusetts (01719 Re: K040121 Trade/Device Name: DermaWave 5000 Combi Max System Regulation Numbers: 21 CFR §890.5860, 21 CFR §890.5300, 21 CFR §882.5890, 21 CFR §882.1320, 21 CFR §890.5500 Regulation Names: Ultrasound and Muscle Stimulator, Ultrasonic diathermy, Transcutaneous electrical nerve stimulator for pain relief, Cutaneous electrode, Infrared lamp Regulatory Class: II Product Codes: IMG, IMI, GZJ, GXY, LIH, ILY Dated: March 3, 2004 Received: March 5, 2004 Dear Mr. Reuber: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {4}------------------------------------------------ Page 2 - Mr. Dcrwyn Reuber This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Mark N. Millican Celia M. Witten, PhD, MD Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ # Indications for Use 510(k) Number (if known): K040121 Device Name: DermaWave :500 Combi Max Indications for Use: Stimulation, relaxing, and/or repeatedly contracting muscles by passing electrical currents through electrodes contacting the affected body area in the medical specialties of physical medicine, general and plastic surgery and neurology and/or for use in applying therapeutic deep heat for selected medical conditions such as relief of pain, muscle spasms and joint contractures in the medical specialty of physical medicine. The indications of the DermaWave 5000 Combi Max System also include the treatment and relaxation of muscle spasms, prevention or retardation of disuse atrophy, increasing local blood circulation, muscle re-education, maintaining or increasing range of motion, immediate postsurgical stimulation of calf rnuscles to prevent venous thrombosis, symptomatic relief of chronic intractable pain, management of pain associated with post-traumatic or post-operative conditions using electrical stimulation and are indicated for the application of therapeutic deep heat for the treatment of selected medical conditions such as relief of pain, muscle spasms and joint contractures, relief of pain muscle spasms and joint contractures that may be associated with adhesive capsulitis, bursitis with slight calcification, myositis, soft tissue injuries, shortened tendons due to past injuries and scar tissucs, relief of chronic and sub-chronic pain and joint contractures resulting from capsular tightness and capsular scarring using ultrasound. The DermaWave 5000 Combi Max System is also indicated for use in providing topical heating for temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, minor pain and stiffness associated with arthritis. Mark A Millhum and Neurologi **510(k) Number** K090121 Over-The-Counter Use Prescription Use X AND/OR (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...